Analysts expect CASI Pharmaceuticals, Inc. to report revenue of 0.00 for 2026, against a range of 0.00 to 0.00. The most recent reported year, 2025, came in at 20.71 M, a 61.2% beat against the 12.85 M consensus.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 30.17 M | 43.11 M | 33.88 M | 28.54 M | 20.71 M | - | - | ||
| High Estimate | 33.33 M | 46.53 M | 39.97 M | 22.31 M | 13.61 M | 0.00 | 91.47 M | ||
| Low Estimate | 28.92 M | 39.96 M | 34.59 M | 19.80 M | 12.08 M | 0.00 | 75.89 M | ||
| Consensus Estimate | 31.12 M | 43.25 M | 37.28 M | 21.05 M | 12.85 M | 0.00 | 83.68 M |
Analysts expect CASI Pharmaceuticals, Inc. to report earnings per share of -2.67 for 2025, against a range of -2.77 to -2.57. The most recent reported year, 2024, came in at -2.56, a 5.3% miss against the -2.43 consensus.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -2.70 | -3.01 | -2.02 | -2.56 | - | - | |||
| High Estimate | -2.60 | -0.98 | -1.64 | -2.33 | -2.57 | -1.33 | |||
| Low Estimate | -3.14 | -1.18 | -1.96 | -2.53 | -2.77 | -1.63 | |||
| Consensus Estimate | -2.87 | -1.08 | -1.80 | -2.43 | -2.67 | -1.48 |
Pull Wall Street consensus for CASI Pharmaceuticals, Inc. (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/estimates?ticker=CASIF&mode=revenue&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/estimates"
params = {"ticker": "CASIF", "mode": "revenue", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/estimates?ticker=CASIF&mode=revenue&api_key=YOUR_API_KEY");
const data = await res.json();